Advancing a broad pipeline of differentiated product candidates for chronic inflammatory diseases.
Development Pipeline
Driving meaningful advances to address chronic inflammation.
We’re committed to evolving immunology, with a pipeline of programs specifically designed to address inflammatory diseases with clear, unmet needs. The disease pathways under investigation by Evommune exert influence on a multitude of disease areas, and the modulation of mast cell, sensory neuron and T-cell activity shows promise in multiple established patient populations.
Program
Target
IL-18
Indication
Stage
Atopic Dermatitis
Ulcerative Colitis
Phase 2
Phase 1
Program
Target
MRGPRX2
Indication
Stage
Migraine
Phase 2
Program
Target
VAV1
Indication
Stage
Rheumatoid Arthritis
Pre-Clinical
Pre-Clin.
Program
Target
TLR 7/8
Indication
Stage
Autoimmune Diseases
Pre-Clinical
Pre-Clin.